ANI Pharmaceuticals Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

ANI Pharmaceuticals exceeded revenue expectations by 2.7% but fell short of earnings per share estimates. Forecast shows 8.8% revenue growth in the next 3 years, slightly lower than the industry average. A warning sign for ANI Pharmaceuticals was also highlighted.